Home › Therapeutic areas › Neurology › Major Depressive Disorder

Major Depressive Disorder (13 companies)

Companies with an active program in Major Depressive Disorder.

Ticker Company Therapeutic areas Programs Lead stage Mkt cap Programs
ANRO Alto Neuroscience Neurology 4 Phase 2 $999M 6
ATAI Atai Beckley Neurology 3 Phase 2 $2.73B 5
AXSM Axsome Therapeutics Neurology Rare 2 Approved $7.15B 15
CMPS COMPASS Pathways Neurology 1 NDA Submitted $1.13B 3
CTNM Contineum Therapeutics NeurologyRespiratory Rare 1 Phase 2 $375M 4
DFTX Definium Therapeutics Neurology 1 Phase 3 $4.02B 4
GHRS GH Research NeurologyWomen's Health 2 Phase 2 $1.25B 4
HELP Helus Pharma Neurology 1 Phase 3 $575M 3
LBRX LB Pharmaceuticals Neurology 1 Phase 3 $1.30B 3
NRXP NRX Pharmaceuticals Neurology Rare 4 Approved $109M 11
RVPH Reviva Pharmaceuticals CardiovascularDermatology+3 Rare 2 Phase 3 $4.7M 11
VNDA Vanda Pharmaceuticals CardiovascularDermatology+6 Rare 1 Approved $230M 27
XENE Xenon Pharmaceuticals Neurology Rare 1 NDA Submitted $3.81B 9